| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
tumor protein p53 | 0.236 | 0.962 | 0.53 |
|
group | 0.100 | None | 0.967 | 2539 | 37 | 1986 | 2020 | ||||||||
|
BRCA1 DNA repair associated | 0.367 | 0.923 | 9.2E-29 |
|
group | 0.100 | None | 0.968 | 808 | 22 | 1993 | 2020 | ||||||||
|
epidermal growth factor receptor | 0.295 | 0.885 | 0.37 |
|
group | 0.100 | None | 0.982 | 950 | 18 | 1990 | 2020 | ||||||||
|
BRCA2 DNA repair associated | 0.379 | 0.846 | 2.4E-25 |
|
group | 0.100 | None | 0.958 | 427 | 15 | 1995 | 2020 | ||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
group | 0.070 | None | 1.000 | 7 | 15 | 2008 | 2019 | |||||||||
|
APC regulator of WNT signaling pathway | 0.373 | 0.962 | 1.00 |
|
group | 0.100 | None | 0.940 | 100 | 14 | 1992 | 2020 | ||||||||
|
ATM serine/threonine kinase | 0.374 | 0.885 | 5.6E-47 |
|
group | 0.100 | None | 0.953 | 215 | 13 | 1995 | 2020 | ||||||||
|
mutL homolog 1 | 0.399 | 0.808 | 3.4E-05 |
|
group | 0.100 | None | 0.945 | 182 | 13 | 1985 | 2020 | ||||||||
|
mutS homolog 2 | 0.406 | 0.808 | 0.90 |
|
group | 0.100 | None | 0.945 | 145 | 12 | 1985 | 2020 | ||||||||
|
PMS1 homolog 2, mismatch repair system component | 0.484 | 0.808 | 4.5E-27 |
|
group | 0.100 | None | 0.941 | 34 | 12 | 2000 | 2019 | ||||||||
|
exonuclease 1 | 0.578 | 0.692 | 8.1E-13 |
|
group | 0.100 | None | 0.882 | 17 | 11 | 2003 | 2019 | ||||||||
|
telomerase reverse transcriptase | 0.374 | 0.846 | 0.99 |
|
group | 0.100 | None | 0.966 | 178 | 10 | 1999 | 2020 | ||||||||
|
estrogen receptor 1 | 0.324 | 0.962 | 1.00 |
|
group | 0.100 | None | 0.945 | 253 | 9 | 1993 | 2020 | ||||||||
|
caveolin 1 | 0.388 | 0.885 | 8.3E-03 |
|
group | 0.100 | None | 0.959 | 97 | 9 | 1998 | 2019 | ||||||||
|
checkpoint kinase 2 | 0.460 | 0.808 | 1.2E-24 |
|
group | 0.100 | None | 0.976 | 83 | 9 | 2001 | 2020 | ||||||||
|
MDM2 proto-oncogene | 0.362 | 0.846 | 1.00 |
|
group | 0.100 | None | 0.980 | 255 | 8 | 1992 | 2020 | ||||||||
|
caspase 3 | 0.351 | 0.923 | 0.10 |
|
group | 0.100 | None | 0.979 | 94 | 8 | 1998 | 2020 | ||||||||
|
O-6-methylguanine-DNA methyltransferase | 0.412 | 0.885 | 1.2E-07 |
|
group | 0.100 | None | 0.976 | 82 | 8 | 1995 | 2019 | ||||||||
|
ERCC excision repair 2, TFIIH core complex helicase subunit | 0.420 | 0.846 | 7.1E-20 |
|
group | 0.100 | None | 0.929 | 56 | 8 | 2000 | 2019 | ||||||||
|
cytochrome P450 family 1 subfamily B member 1 | 0.457 | 0.769 | 2.2E-05 |
|
group | 0.100 | None | 0.973 | 37 | 8 | 1979 | 2020 | ||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
group | 0.030 | None | 1.000 | 3 | 8 | 2017 | 2018 | |||||||||
|
CD44 molecule (Indian blood group) | 0.363 | 0.962 | 2.4E-07 |
|
group | 0.100 | None | 0.984 | 430 | 7 | 1992 | 2020 | ||||||||
|
phosphatase and tensin homolog | 0.305 | 0.923 | 0.26 |
|
group | 0.100 | None | 0.975 | 355 | 7 | 1997 | 2020 | ||||||||
|
KRAS proto-oncogene, GTPase | 0.320 | 0.923 | 7.9E-04 |
|
group | 0.100 | None | 0.977 | 352 | 7 | 1987 | 2020 | ||||||||
|
mechanistic target of rapamycin kinase | 0.343 | 0.885 | 1.00 |
|
group | 0.100 | None | 0.984 | 190 | 7 | 1995 | 2020 |